Supplementary Materials

Progression of bone-metastatic prostate cancer in a mouse model treated with a novel pan-class I GLUT inhibitor (DRB18)

Nathan K. Hoggard[1], Shiyu Yuan[2,9], Marlon R. Szczepaniak[1], Megan M. Turner[3], Noriko Kantake[1], Chunmin Lo[1], Zachary D. LaRussa[1,2], Jingwen Song[2], Nigel A. Daniels[7], Jonathan A. Young[8], John B. Echols[7], Blake E. Hildreth III[8], Stephen C. Bergmeier[4], Xiaozhuo Chen[1,4,5], Thomas J. Rosol[1,6]

[1]Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
[2]Department of Biological Sciences, College of Arts and Sciences, Ohio University, Athens, OH 45701, USA.
[3]Department of Biological Sciences, Honors Tutorial College, Ohio University, Athens, OH 45701, USA.
[4]Department of Chemistry and Biochemistry, College of Arts and Sciences, Ohio University, Athens, OH 45701, USA.
[5]Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA.
[6]Ohio Musculoskeletal and Neurological Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
[7]Genomics Facility, College of Arts and Sciences, Ohio University, OH 45701, USA.
[8]Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
[9]Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Correspondence to: Dr. Thomas Rosol, Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, 1 Ohio University, 349 Irvine Hall, Athens, OH 45701, USA. E-mail: rosolt@ohio.edu

Supplementary Table 1. Average qRT-PCR GLUT gene expression for PCa cell lines

Gene Expression	Ace-1	Probasco	LuMa	Leo	PC3
SLC2A1 Ct	27.2	28.6	26.9	26.7	23.4
SLC2A1 Del Ct	7.2	8.4	7.7	7.8	6.2
SLC2A3 Ct	NE	23.6	25.1	22.0	26.8
SLC2A3 Del Ct	NE	3.4	6.0	2.9	9.3
SLC2A4 Ct	NE	NE	NE	NE	29.0
SLC2A4 Del Ct	NE	NE	NE	NE	11.8

Ct: cycle threshold; Del Ct: delta cycle threshold (mathematic difference between Ct of target gene and housekeeping gene); NE: not expressed.



Supplementary Figure 1. *In vitro* dose-dependent effects of DRB18 on Ace-1 and Probasco cell lines. (A). Ace-1 cells were treated with DRB18 for 72h in standard complete growth media. (B). Ace-1 cells were grown in DMEM low glucose media and treated with 5, 10, 20, 30, 40, and 50 μM DRB18 for 24 h. (C). Ace-1 cells were grown in RPMI media and treated with 5, 10, 20, 30, 40, and 50 μM DRB18 for 24 h. Relative cell viability was determined as a percentage of vehicle (DMSO)-treated control cells. (D). DRB18 inhibited glucose uptake in a dose-dependent manner. Probasco cells were seeded in triplicate and treated with increasing doses of DRB18 for 15 min. Uptake of 2-deoxy-D-[3H] glucose was quantified by scintillation. Data were displayed as mean ± SD. One-way ANOVA. **P* < .05; ***P* < .01.

Supplementary Table 2. Autopsy Relative Organ Weights

Parameter	Control	Treated	
	Mean ± SD		*P*-value
Heart (%)	0.52 ± 0.03	0.54 ± 0.09	NS
Liver (%)	4.7 ± 0.41	4.5 ± 0.52	NS
Right Kidney (%)	0.93 ± 0.05	0.97 ± 0.08	NS
Left Kidney (%)	0.96 ± 0.07	0.93 ± 0.09	NS

NS: Not significant.